Merrimack forms partnership with cancer treatment centres to access tumour samples
This article was originally published in Scrip
Executive Summary
Merrimack Pharmaceuticals is collaborating with the Cancer Treatment Centers of America (CTCA) to inform its research and development of diagnostics that identify the best patients for the company's cancer therapies with the long-term goal of developing a genetic test that sorts through several oncology drugs to find the best treatment for each patient.